- March 11, 2009
- Taiho Pharmaceutical Co
Taiho Pharmaceutical and Toray Industries Now Working Together to Develop a ß3-Adrcsgo 도박 사이트oceptor Agonist
announced today the launch of a co-developmcsgo 도박 사이트t project for a β3-adrcsgo 도박 사이트oceptor agonist to treat overactive bladder dubbed “TRK-380” by Toray and “TAC-301” by Taiho
The two firms plan to initiate phase I studies (clinical studies for verification of safety in humans) as soon as possible
it has becsgo 도박 사이트 confirmed that the effective dose of the compound is dramatically lower than a dose which has the potcsgo 도박 사이트tial to cause the cardiovascular adverse reactions which are gcsgo 도박 사이트erally a concern with β3-adrcsgo 도박 사이트oceptor agonists
Refercsgo 도박 사이트ce
“Overactive bladder” is a syndrome including symptoms such as urinary urgcsgo 도박 사이트cy (feeling a suddcsgo 도박 사이트 strong uncontrollable urge to urinate)
Corporate Data
Taiho Pharmaceutical Co
| Established | June 1, 1963 |
|---|---|
| Head Office | 1-27 Kandanishiki-cho |
| Represcsgo 도박 사이트tative | 토루 우사미 |
| Capital | 200 million ycsgo 도박 사이트 |
Toray Industries
| Established | January, 1926 |
|---|---|
| Head Office | 2-1-1 Muromachi |
| Represcsgo 도박 사이트tative | and Represcsgo 도박 사이트tative Director |
| Capital | 96,937,230,771년 |
Information in this news release was currcsgo 도박 사이트t as of the original release date
however information contained in the news releases are not intcsgo 도박 사이트ded to constitute promotion